

A Mid-sized Sponsor Increased its Potential Site List for a Rare Disease Clinical Trial by 50% with Medidata AI Intelligent Trials

Challenge

As they embarked on an upcoming rare disease clinical trial, a mid-sized biopharmaceutical company was struggling with patient recruitment and site selection. The company needed to identify sites with the greatest access to patients and highest enrollment performance but did not have deep enough data to make confident decisions.

While there are approximately 7,000 rare diseases, 95% of these conditions do not have an FDA-approved treatment.¹ This figure is impacted by many factors, including small patient populations and changing trial conditions. Between 2016 and 2020, over a quarter of rare disease trials were terminated due to low patient accrual rates.² In such a challenging indication, it was critical for this mid-sized sponsor to choose high-performing sites based on reliable data to set their trial up for success.

Solution

The biopharmaceutical company partnered with Medidata AI to identify high-performing sites for their upcoming trial. Intelligent Trials is the only clinical trial analytics solution that brings together cross-industry performance metrics from 1,900+ customers and 27,000+ trials with granularity at the country and site level, real-time insights into the current competitive landscape, and predictive modeling capabilities to give sponsors a competitive edge.

The Medidata AI team worked directly with the sponsor to identify the criteria that were important for site selection. Then, the team's insights highlighted sites with strong enrollment performance in industry studies. Medidata AI refreshed these insights every quarter, giving the sponsor access to the latest data and new sites as they came online.

Results

Medidata AI provided site recommendations based on the identified priority operational metrics, including enrollment performance and data quality. The team also provided insights based on the company's historical performance at those sites compared to the industry. Ultimately, Medidata AI was able to increase the company's pool of available sites for site selection with specific experience in this rare disease by 50%.

50%

Increase in sites available to company for site selection, with specific experience in this rare disease, based on Medidata AI data

1,2 Over 25% of rare disease trials are terminated due to low patient accrual rates, says GlobalData. GlobalData. Available from: <https://www.globaldata.com/25-rare-disease-trials-terminated-due-low-patient-accrual-rates-says-globaldata/>